Cyclotide patent set for approval in Europe
The European Patent Office (EPO) is expected to approve Cyxone's cyclotide patent application, on which the company is basing its multiple sclerosis development project, at the beginning of next year. This will enable the company to subsequently select the European countries where this application will be validated and local patents can then be issued. KontaktCyxone AB (publ)Kjell G. Stenberg, CEOTel: 0723-816168E-post: kjell.g.stenberg@cyxone.comAdelgatan 21211 22 Malmö Om CyxoneCyxone AB (publ) är ett biomedicinskt bolag som utvecklar läkemedel baserat på en typ av